aberrations and match more than enough to tolerate FCR therapy, may still be fantastic candidates for that latter, Together with the advantage being that this treatment is usually completed in six months although ibrutinib needs to be taken indefinitely.Some degree of immunophenotype overlap amongst CLL, marginal zone lymphoma, and lymphoplasmacyti